shown for the test using fried karela for the sake of clarity. *p <0-05. **p <0o01. Conversion: SI to traditional unite-Glucose: 1 mmol/l 18 mg/100 ml.
Insulin concentrations with karela in the diabetics and rats were significantly different from the results in the standard test only twice. The initial concentration in the test with karela juice added was significantly higher than that in the standard test (31-3±13 7 v 246±10-6 mU/l; p<005); and the concentration at 60 minutes in the test after the patients had taken fried karela was significantly lower than that in the standard test (42-3±22-8 v 75-2±50 5 mU/l; p<0 05).
Glycosylated haemoglobin was 17 9±3 1°' after patients had taken fried karela, which was significantly different (p<001) from the results obtained in the standard test (196±22%20) and in the test with added karela juice (19-2 ±2 0%).
Discussion
We have confirmed the hypoglycaemic effect of karela juice in animals3 and shown that it is not due to hyperinsulinaemia; previous studies have shown that it does not result from reduced intestinal absorption.4 Our study has shown clearly for the first time that karela improves glucose tolerance in diabetes, confirming previous anecdotal reports.' 5 The effect was most pronounced with raw juice, but a small improvement occurred with fried karela.
As serum insulin concentrations were not increased karela may directly influence hepatic or peripheral glucose disposal. The reduction in glycosylated haemoglobin in patients receiving hypoglycaemic agents suggests an extrapancreatic effect. Karela has been used extensively in fringe medicine without serious side effects and merits further study. Doctors supervising Asian diabetics should be aware of its hypoglycaemic properties. Labetalol is a relatively new hypotensive agent, with competitive antagonist activity in both alpha-and beta-adrenergic receptors., Its effectiveness in the treatment of hypertension has not been impeded by serious side effects. Rare instances of muscle pain during treatment have been mentioned in the published reports,24 but there has been no report of labetalol-induced toxic myopathy. We describe a case in which labetalol treatment was complicated by toxic myopathy, which disappeared when the drug was withdrawn and withdrawal of the drug resulted in disappearance of the condition.
Case report
A 27-year-old man was found to have hypertension on routine examination. After an intensive investigation essential hypertension was confirmed and treatment begun with chlorthalidone 100 mg/day. Subsequently, clonidine 0 6 mg daily was added. Two years later, when the patient became resistant to these medicines and blood pressure rose to 106/110 mm Hg, labetalol 600 mg/day was prescribed instead.
While on this treatment the man began to complain of muscle pain, especially in the legs. Neurological examination did not show any abnormality: the muscle strength was normal, there was no wasting, and reflexes were normal. The activities of muscle enzymes in the blood-creatine phosphokinase, lactic dehydrogenase, and aldolasewere persistently high. Triiodothyronine and thyroxine concentrations were normal. On electrodiagnostic study the motor-nerve conduction velocity from ulnar, peroneal, and posterior tibial nerves on both sides was normal. The electromyogram from both gastrocnemius muscles showed increased insertion activity. On rest there was spontaneous activity with fibrillation potentials and positive sharp waves. On voluntary contraction the interference pattern was not full and there were many polyphasic potentials; motor unit potentials were in low amplitude and short duration. Myotonic reaction was not found. The electromyogram findings were compatible with myositis, and a biopsy specimen was taken from the deltoid muscle. Light microscopy did not show any histological changes, and the histochemical examination (adenosinetriphosphatase succinic dehydrogenase staining) showed a normal typing of muscle fibres. Electronmicroscopy study showed many vacuoles of various sizes in the sarcoplasm under the sarcolemma, without staining and without connection to any structure in the cell. (fig 1) . These findings confirmed non-specific toxic myopathy. The 2..~~~~~~. labetalol was stopped for 10 days, during which time the muscle pains disappeared and the enzyme activities returned to normal. A few days later, and after we had obtained the informed consent of the patient, we restarted the labetalol. The muscle pain reappeared soon and serum muscle enzyme activities rose (fig 2) . Labetalol was stopped and atenolol 100 mg/twice daily was prescribed, with effective response and with no adverse reaction.
Discussion
Muscle pain and cramp in the calves have been mentioned in only a few studies on labetalol, and they disappeared within a short time without the necessity of stopping the drug. Several drugs may induce muscle disorder, including steroids, anti- 
